This guidance document comes after AllTrials, an international initiative, launched a tracking tool in February 2018 that publicly discloses which research entities have not reported data from clinical trials.
Last month, the FDA published a draft guidance document relating to potential fines that may be incurred if submitters of data and trial information on clinicaltrials.gov either do not report clinical trial results, or misreport findings.
The document, “Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank,” explains that under section 303(f)(3) of the Federal Food, Drug and Cosmetic Act (FD&C Act), the FDA is authorized to assess civil money penalties against responsible parties and/or submitters of applications for drug products, biologics, and devices.
The guidance also answered some general questions, such as how the FDA intends to identify whether an organization or someone has failed to submit required clinical trial registration and/or results to the data bank or submitted false information. The FDA plans to identify such violations through evidence collected during inspections, as well as through complaints received by the agency.
If the agency has deemed that a party has failed to comply with regulation, it “intends to send the responsible party a Preliminary Notice of Noncompliance (Pre-Notice) Letter, which describes the potential violation and requests that the responsible party review the record in the ClinicalTrials.gov data bank and make any necessary corrections within 30 days,” read the document. If the violation has not been addressed in the 30 days, the agency will then send a Notice of Noncompliance, which allows the party an additional 30 days to remedy the situation.
Should a civil money penalty be assessed, the statutory maximum penalties under the FD&C Act are no more than $10,000 for all violations adjudicated in a single proceeding. In addition, if a violation is not corrected within the 30 days following notification of a violation, an organization can be fined up to, but not more than, $10,000 per day the violation continues.
This guidance document comes after AllTrials, an international initiative, launched a tracking tool in February 2018 that publicly discloses which research entities have not reported data from clinical trials.
Included in the announcement of the initiative was an open letter to FDA Commissioner Scott Gottlieb, MD, that noted that the FDA has the power to sanction such violators and institute fines against clinical trial sponsors that fail to report trial results, and urged the Commissioner to do just that.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.